Literature DB >> 12975296

Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex.

Steven P Sparagana1, Mauricio R Delgado, Lori L Batchelor, E Steve Roach.   

Abstract

BACKGROUND: Epilepsy is a common neurologic complication of tuberous sclerosis complex (TSC) and it is often refractory to treatment. Therefore, treating physicians are often reluctant to discontinue antiepileptic drugs (AEDs) in individuals with TSC who have attained seizure remission. To our knowledge, seizure remission and AED discontinuation in children with TSC has not been studied.
OBJECTIVE: To characterize seizure remission and AED discontinuation in children with TSC.
METHODS: Retrospective medical record and neuroimaging analysis of 15 children with TSC and epilepsy who had seizure remission, with a subsequent trial of discontinuation of AED treatment.
RESULTS: The seizure remission rate for the group of patients with TSC and epilepsy was 14.2%. From the group of 15 patients who had a remission, the absolute relapse rate was 26.7% after a mean follow-up of 5 years 7 months. Patients with sustained remission were more likely to have normal intelligence and only a few cortical or subcortical lesions on neuroimaging.
CONCLUSIONS: The proportion of children with TSC and epilepsy who achieve seizure remission is small. Nevertheless, some do attain seizure remission, and AEDs may be successfully discontinued. Mild cerebral involvement is a general clinical marker for seizure remission. The relapse rate in those who have undergone a trial of discontinuation of AED therapy is comparable with the rate in the general pediatric population with epilepsy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975296     DOI: 10.1001/archneur.60.9.1286

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

Review 1.  Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2007-08-28       Impact factor: 5.864

Review 2.  Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.

Authors:  Michael Wong
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

Review 3.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

4.  Factors affecting epilepsy prognosis in patients with tuberous sclerosis.

Authors:  Gülen Gül Mert; Şakir Altunbaşak; Özlem Hergüner; Faruk İncecik; Hilal Cansever Övetti; Neslihan Özcan; Duygu Kuşçu; İlker Ünal
Journal:  Childs Nerv Syst       Date:  2019-01-23       Impact factor: 1.475

5.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

6.  Brain MR spectroscopic abnormalities in "MRI-negative" tuberous sclerosis complex patients.

Authors:  William E Wu; Ivan I Kirov; Assaf Tal; James S Babb; Sarah Milla; Joseph Oved; Howard L Weiner; Orrin Devinsky; Oded Gonen
Journal:  Epilepsy Behav       Date:  2013-03-22       Impact factor: 2.937

7.  Impaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex.

Authors:  Lin Xu; Ling-Hui Zeng; Michael Wong
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

Review 8.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

9.  The natural history of epilepsy in tuberous sclerosis complex.

Authors:  Catherine J Chu-Shore; Philippe Major; Susana Camposano; David Muzykewicz; Elizabeth A Thiele
Journal:  Epilepsia       Date:  2009-12-22       Impact factor: 5.864

10.  Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants.

Authors:  Joyce Y Wu; Jurriaan M Peters; Monisha Goyal; Darcy Krueger; Mustafa Sahin; Hope Northrup; Kit Sing Au; Gary Cutter; E Martina Bebin
Journal:  Pediatr Neurol       Date:  2015-09-25       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.